Lucitanib
Lucitanib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target platelet-derived growth factor receptor alpha, proto-oncogene tyrosine-protein kinase receptor Ret, mast/stem cell growth factor receptor Kit, vascular endothelial growth factor receptor 1, platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, and fibroblast growth factor receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | 2 | 2 | — | — | 2 |
| Heartburn | D006356 | — | R12 | — | — | 2 | — | — | 2 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 1 | — | — | 1 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 4 | — | — | — | 6 |
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Female genital neoplasms | D005833 | — | — | 1 | 1 | — | — | — | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lucitanib |
| INN | lucitanib |
| Description | E-3810 free base is a naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine. It has a role as an antineoplastic agent, a fibroblast growth factor receptor antagonist and a vascular endothelial growth factor receptor antagonist. It is a member of quinolines, an aromatic ether, a member of cyclopropanes, a primary amino compound and a naphthalenecarboxamide. It is a conjugate base of an E-3810(1+). |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12 |
Identifiers
| PDB | — |
| CAS-ID | 1058137-23-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2220486 |
| ChEBI ID | 65209 |
| PubChem CID | 25031915 |
| DrugBank | — |
| UNII ID | PP449XA4BH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDGFRA
PDGFRA
RET
RET
KIT
KIT
FLT1
FLT1
PDGFRB
PDGFRB
KDR
KDR
FGFR1
FGFR1
Organism
Homo sapiens
Gene name
PDGFRA
Gene synonyms
PDGFR2, RHEPDGFRA
NCBI Gene ID
Protein name
platelet-derived growth factor receptor alpha
Protein synonyms
Alpha platelet-derived growth factor receptor, Alpha-type platelet-derived growth factor receptor, CD140 antigen-like family member A, CD140a, CD140a antigen, PDGF-R-alpha, PDGFR-2, Platelet-derived growth factor alpha receptor, Platelet-derived growth factor receptor 2, platelet-derived growth factor receptor, alpha polypeptide
Uniprot ID
Mouse ortholog
Pdgfra (18595)
platelet-derived growth factor receptor alpha (Q8C4N3)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 373 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use